Business Wire

NZMP: New Research Hopes to Unlock Understanding of How the Gut and Brain Interact

Jaa

NZMP SureStart™, the global B2B paediatric ingredients brand of Fonterra, announces today it is part of Smarter Lives, a five-year research programme to investigate how nutrition impacts the gut-brain axis.

Smarter Lives is funded by New Zealand’s Ministry of Business, Innovation and Employment and is led by New Zealand research institute, AgResearch. It will investigate how foods influence brain function via the sophisticated communication systems between the gut and the brain.

Fonterra’s Programme Manager Nutrition and Health, James Dekker, says, “The gut is sometimes referred to as ‘the second brain’, and the Smarter Lives research programme will help to explore what is meant by this.

There has been a significant amount of research into the role of dairy ingredients in cognition and gut health. However, more work is needed to understand the gut-brain axis and what this means for paediatric nutrition.

“For example, we know ingredients like NZMP SureStart™ Lipid 100 may offer both digestive health and cognition benefits, but we don’t fully understand how these two functions correlate.

“Another study has found levels of good gut bacteria were increased in formula fed infants consuming SureStart™ BifidoB 019, showing the ingredient’s effect on gut microbiota1. However, we don’t completely understand how ingredients like SureStart™ BifidoB 019 impact behaviours and cognition,” says James.

The research is supported by the Riddet Institute, the Centre for Brain Research and Fonterra Research and Development Centre, in collaboration with international researchers at Flinders University, Illinois University and University College Cork.

“We know the first years of a child’s life are a sensitive period during which the child’s brain is most receptive to the effects of nutrition and its environment. Both are vital for the optimal development of the brain.

“The Smarter Lives research programme will build on existing research and unlock how we can influence the two-way communication between the gut and the brain to help to optimise cognitive development in formula fed infants,” says James.

What is the Gut-Brain Axis?

There is a vast network of neurons, called the enteric nervous system, that line the gut. Research has found that a direct line of two way communication exists between the brain and the enteric nervous system. This means that influences on the gut and its functions, such as diet, can impact signals sent to the brain.

Breast milk is the ideal source of nutrition for infants. Breast milk is the best nutrition you can give to your baby. It’s full of everything a baby needs to grow and develop in a healthy way and gives children the very best start in life. Breast milk substitutes are recognised by the World Health Organisation as safe and nutritious alternatives to breast milk for infants whose mothers cannot, or choose not to, breastfeed.

1 Oswari H, Prayitno L, Dwipoerwantoro PG, et al. Comparison of stool microbiota compositions, stoppl alpha1-antitrypsin and calprotectin concentrations, and diarrhoeal morbidity of Indonesian infants fed breast milk or probiotic/prebiotic-supplemented formula. Journal of Paediatrics and Child Health (2013).

About Smarter Lives

NZ-based AgResearch scientists leading a research programme looking at the future of foods to boost the brain. More than $12 million has been awarded by the NZ Ministry of Business, Innovation and Employment's Endeavour Fund for this research.

The project is called 'Smarter Lives: New opportunities for dairy products across the lifespan', and is focused on how foods can influence brain performance via the ''gut-brain axis''. This research is undertaken in collaboration with Fonterra, the Riddet Institute, The University of Auckland's Centre for Brain Research, Australia's Flinders University, Ireland's University College Cork, and Illinois University in the United States.

About SureStart™

SureStart™ is NZMP’s paediatric ingredients brand. NZMP has a long heritage in paediatric innovation. Inspired by breast milk composition from the beginning, NZMP invests in world-leading research. This underpins SureStart™ ingredient innovation, and enables NZMP to be at the forefront of paediatric nutrition. SureStart™ focus areas are cognition, protection, digestive health and growth and development. Visit www.surestartnutrition.com for more information.

About NZMP

NZMP is the global dairy ingredients brand of Fonterra. Trusted globally, NZMP ingredients are sold in more than 130 countries and can be found at the heart of some of the world’s most famous food and nutrition brands. NZMP has one of the broadest ranges of ingredients in the dairy industry, providing hundreds of solutions to meet the needs of customers and consumers every day.

Backed by Fonterra, NZMP draws on New Zealand’s grass-fed farming heritage and expertise, world-class processing and leading quality standards. NZMP ingredients deliver a market advantage, trusted for their high performance and exceptional quality. www.nzmp.com

Contact information

For further information or to organise an interview contact:
Porter Novelli on behalf of NZMP
Adam Szentes, +64 21 265 1067
adams@porternovelli.kiwi

Tietoja julkaisijasta

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Tilaa tiedotteet sähköpostiisi

Haluatko tietää asioista ensimmäisten joukossa? Kun tilaat mediatiedotteemme, saat ne sähköpostiisi välittömästi julkaisuhetkellä. Tilauksen voit halutessasi perua milloin tahansa.

Lue lisää julkaisijalta Business Wire

Schlumberger Announces Fourth-Quarter and Full-Year 2018 Results Conference Call16.11.2018 21:00Tiedote

Schlumberger Limited (NYSE:SLB) will hold a conference call on January 18, 2019 to discuss the results for the fourth quarter and full year ending December 31, 2018. The conference call is scheduled to begin at 8:30 am US Eastern time and a press release regarding the results will be issued at 7:00 am US Eastern time. To access the conference call, listeners should contact the Conference Call Operator at +1 (800) 288-8967 within North America or +1 (612) 333-4911 outside of North America approximately 10 minutes prior to the start of the call, and ask for the “Schlumberger Earnings Conference Call.” A webcast of the conference call will be broadcast simultaneously at www.slb.com/irwebcast on a listen-only basis. Listeners should log in 15 minutes prior to the start of the call to test their browsers and register for the webcast. Following the end of the conference call, a replay will be available at www.slb.com/irwebcast until February 18, 2019, and can be accessed by dialing +1 (800)

Visa Strengthens Commitment to Growing Digital Payments in India16.11.2018 17:33Tiedote

Visa (NYSE: V) today announced a minority investment in BillDesk, a leading platform for online payments and bill payments in India. Visa’s investment and collaboration will help BillDesk develop new product lines for its payments and loyalty businesses and also expand its footprint into other geographies. The investment will be subject to necessary statutory approvals and is expected to have no direct bearing on Visa’s existing Indian business. “As a leading payments player in India, BillDesk has been a long time business partner to Visa. Having worked with BillDesk’s founders over the years, the Visa leadership has been consistently impressed with their vision, market knowledge and execution capabilities, as well as alignment on values. This investment further reinforces our long-term commitment to India’s digital payments growth story,” said Asia Pacific regional president, Chris Clark. “We are truly excited by this investment from the world's largest global payment network, Visa. W

Guidewire Enhances PartnerConnect Consulting Program with Addition of Product and Regional Specializations16.11.2018 16:55Tiedote

Guidewire Software, Inc. (NYSE: GWRE), provider of the industry platform Property and Casualty (P&C) insurers rely upon, today announced the addition of specializations to its PartnerConnect Consulting program. Specializations have been added to aid insurance companies in selecting the best partner to lead or staff their Guidewire projects. Guidewire unveiled new specializations, including two which have been successfully piloted earlier this year. “Our customers will now have more clarity and information as to which partners have the proven capabilities in their chosen product and region,” said Lisa Walsh, vice president, Alliances, Guidewire Software. “Adding these specializations will also allow us to have more insight into a partner’s performance and competencies.” To earn a specialization, partners need to demonstrate skills, knowledge, and competency in a specific Guidewire product or solution by certifying staff at multiple levels (specialist and professional) through Guidewire’

Janssen receives positive CHMP opinion for ERLEADA™ (apalutamide) for patients with non-metastatic castration-resistant prostate cancer who are at high risk of developing metastatic disease16.11.2018 16:15Tiedote

The Janssen Pharmaceutical Companies of Johnson & Johnson today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion for apalutamide, a next generation oral androgen receptor inhibitor for the treatment of adult patients with non-metastatic castration-resistant prostate cancer (nmCRPC) who are at high risk of developing metastatic disease.2 The CHMP’s positive opinion will now be reviewed by the European Commission (EC), which has the authority to grant approval for the use of apalutamide. The CHMP’s positive opinion is based on data from the pivotal SPARTAN Phase 3 clinical study which assessed the safety and efficacy of apalutamide versus placebo in patients with nmCRPC who have a rapidly rising prostate specific antigen (PSA) level despite receiving continuous androgen deprivation therapy (ADT). The SPARTAN clinical study showed that apalutamide, when added to ADT, significantly reduced the risk

Vertex Receives European CHMP Positive Opinion for ORKAMBI® (lumacaftor/ivacaftor) for Treatment of Children with Cystic Fibrosis Aged 2 to 5 Years Old with Most Common Form of the Disease16.11.2018 15:57Tiedote

Vertex Pharmaceuticals (Europe) Limited today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion for ORKAMBI® (lumacaftor/ivacaftor) for the treatment of people with cystic fibrosis (CF) aged 2 to 5 years old who have two copies of the F508del mutation, the most common form of the disease. If the European Commission issues a favorable adoption of the EMA CHMP opinion for the extension of indication, lumacaftor/ivacaftor will be the first and only medicine approved in Europe to treat the underlying cause of CF for patients aged 2 to 5 years old who have two copies of the F508del mutation. “Cystic fibrosis is a chronic, progressive disease and it is important to treat early to ensure the best possible outcomes for patients,” said Reshma Kewalramani, MD, Executive Vice President, Global Medicines Development and Medical Affairs and Chief Medical Officer at Vertex. “Today’s announcement brings us one step cl

Dimension Data Global Delivery Centre (GDC) in Prague wins the ABSL 2018 Diamond Award for Business Innovation16.11.2018 11:00Tiedote

Dimension Data, the USD 8 billion global technology integrator and managed services provider, today announced that its Global Delivery Centre (GDC) in Prague has won the 2018 ABSL Diamond award for Business Innovation. The main purpose of this centre is to provide innovative, global service delivery capabilities and deep technical expertise to support our clients. The ABSL Diamond awards recognise companies that implement innovative projects, enhancing their business and strengthening the position of the business services sector. Every year, the aim is to identify successful activities in this sector and promote best practices, ultimately encouraging and inspiring others to follow suit. The ABSL celebrates initiatives that push business services forward and stand out as exemplary projects. Bill Padfield, Group Chief Operating Officer for Transformation and Services at Dimension Data, said: “Winning another award for our Support Services is a fantastic achievement. This time the ABSL Di

Uutishuoneessa voit lukea tiedotteitamme ja muuta julkaisemaamme materiaalia. Löydät sieltä niin yhteyshenkilöidemme tiedot kuin vapaasti julkaistavissa olevia kuvia ja videoita. Uutishuoneessa voit nähdä myös sosiaalisen median sisältöjä. Kaikki STT Infossa julkaistu materiaali on vapaasti median käytettävissä.

Tutustu uutishuoneeseemme